Learning from disasters: Saxony fights the floods of the river Elbe 1784-1845

'Seit der Jahrtausendflut 2002 und dem IPCC-Bericht im Frühjahr 2007 kommt das Thema 'Klimaänderung verursacht Naturkatastrophen' in Medien und Wissenschaft nicht mehr zur Ruhe. In diesem Artikel wird der Frage nachgegangen, wie eine Gesellschaft reagiert, wenn sie nahezu ständig von Naturkatastrophen heimgesucht wird. In Sachsen kam es zwischen 1784 und 1845 zu wenigstens zwölf schweren Hochwasserkatastrophen. Die Reaktionen der politisch Verantwortlichen, aber auch der betroffenen Bevölkerung auf diese ständige Konfrontation sind Hauptgegenstand des Artikels. Daraus resultierte eine sächsische Lerngenese aus Gegenmaßnahmen und Lernschritten, die in drei Lernphasen (1784-1800, 1800-1820, 1820-1845) vorgeführt wird. Dem vorgeschaltet sind einführende Erläuterungen zu historischen Aspekten und bisherigen Veröffentlichungen der Naturkatastrophen- und Hochwasserforschung. Ein theoretischer Rahmen zum Lernen aus Katastrophen ist dieser Einführung angegliedert. Im Ausblick wird die sächsische Lerngenese der Studie des DKKV 'Lessons learned' von 2002 gegenübergestellt. Dabei werden nicht nur Analogien zwischen damaligem und heutigem Katastrophenmanagement unterstrichen, sondern die effizienteren Methoden und Vorgehensweisen vor über 200 Jahren herausgestellt.' (Autorenreferat)'After the millennium flood of 2002 in Saxony the subject of 'climate change causes natural disasters' does not come to rest in the media and science. This article investigates how a society reacts, when it is almost constantly struck by natural disasters. Between 1784 and 1845 at least 12 disastrous floods happened in Saxony. The result thereof was a Saxon learning-genesis which is demonstrated in three learning phases (1784-1800, 1800-1820 and 1820-1845). Introductory explanations of historical aspects of and publications about natural disasters and high water research to day are provided. A theoretical framework on how to learn from natural disasters is attached. In the outlook, the Saxon learning genesis is compared to the study of the DKKV (Deutsches Komitee für Katastrophenvorsorge), 'Lessons Learned' from 2003. Thereby not only analogies between previous and today's disaster management are drawn but also are underlined the more efficient methods and approaches of more than 200 years ago.' (author's abstract

Studying the stability of Solvent Red 19 and 23 as excise duty components under the influence of controlled factors

In this study, we examine the chemical stability of two disazo dyes, namely Solvent Red 19 and 23 (SR 19 and SR 23), under simulated conditions. Both dyes are considered to be chemically stable under normal exploitation conditions and therefore, are used extensively as excise duty components that enable a rapid visual verification of the tax levels that were imposed on fuel products as well as identifying fuel usage. However, the results from this study confirmed that the colour of the samples that had been fortified with either SR 19 or SR 23 fades under the influence of external conditions such as UV-A irradiation and temperature over time. The UV-A irradiation was the dominant factor that was responsible for the colour of the samples to fade in two designed experiments that were carried out independently for two model systems. The analysis of the UV/Vis and fluorescence spectra as well as the interpretation of the changes that were observed in the chromatographic profiles provided substantial evidence that the colour fading was caused by the photodegradation of the disazo dyes, which also occurs in non-polar media including fuel products. SR 19 is more stable than SR 23

VIRIM, A Real-Time Volume Rendering System for Medicine

VIRIM, a real-time direct volume rendering system is presented. The system is freely programmable and supports models like a-compositing, front-to-back (back-to-front) techniques, and the slab method. The hardware system is divided into two units, a geometry unit and a raycast unit. The geometry unit performs resampling and gradient estimation and is mapped directly into hardware. It supports different resampling filters in order to reduce resampling artifacts. The raycast unit consists of 16 digital signal processors that perform the programmable ray- casting. The software of VIRIM is layered and provides manipulation tools for the data during real-time visualization like arbitrary gray-value mapping and setting the region of interest. The system is under test and will be available as prototype in 1995

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u27s Disease: A comprehensive review.

Alzheimer\u27s disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accounting for an estimated $290 billion. Cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists have historically been the most widely used pharmacologic therapies for patients with AD; however, these drugs are not curative. The present investigation describes the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, Adulhelm, in the treatment of AD. Currently, Adulhelm is the only Food and Drug Administration (FDA) approved drug that acts to slow the progression of this disease. Adulhelm is an anti-amyloid drug that functions by selectively binding amyloid aggregates in both the oligomeric and fibrillar states. Studies show Adulhelm may help to restore neurological function in patients with AD by reducing beta-amyloid plaques and reestablishing neuronal calcium permeability. At present, there is concern the magnitude of this drug\u27s benefit may only be statistically significant, although not clinically significant. Despite skepticism, Adulhelm has proven to significantly decrease amyloid in all cortical brain regions examined. With such high stakes and potential, further research into Adulhelm\u27s clinical efficacy is warranted in the treatment of AD

Buprenorphine and its formulations: a comprehensive review.

Buprenorphine, a novel long-acting analgesic, was developed with the intention of two purposes: analgesia and opioid use disorder. Regarding its pharmacodynamics, it is a partial agonist at mu receptors, an inverse agonist at kappa receptors, and an antagonist at delta receptors. For the purpose of analgesia, three formulations of buprenorphine were developed: IV/IM injectable formulation (Buprenex®), transdermal patch formulation (Butrans®), and buccal film formulation (Belbuca®). Related to opioid dependence, the formulations developed were subcutaneous extended release (Sublocade®), subdermal implant (Probuphine®), and sublingual tablets (Subutex®). Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations

System Architecture of A European Platform for Health Policy Decision Making: MIDAS

Background: Healthcare data is a rich yet underutilized resource due to its disconnected, heterogeneous nature. A means of connecting healthcare data and integrating it with additional open and social data in a secure way can support the monumental challenge policy-makers face in safely accessing all relevant data to assist in managing the health and wellbeing of all. The goal of this study was to develop a novel health data platform within the MIDAS (Meaningful Integration of Data Analytics and Services) project, that harnesses the potential of latent healthcare data in combination with open and social data to support evidence-based health policy decision-making in a privacy-preserving manner. Methods: The MIDAS platform was developed in an iterative and collaborative way with close involvement of academia, industry, healthcare staff and policy-makers, to solve tasks including data storage, data harmonization, data analytics and visualizations, and open and social data analytics. The platform has been piloted and tested by health departments in four European countries, each focusing on different region-specific health challenges and related data sources. Results: A novel health data platform solving the needs of Public Health decision-makers was successfully implemented within the four pilot regions connecting heterogeneous healthcare datasets and open datasets and turning large amounts of previously isolated data into actionable information allowing for evidence-based health policy-making and risk stratification through the application and visualization of advanced analytics. Conclusions: The MIDAS platform delivers a secure, effective and integrated solution to deal with health data, providing support for health policy decision-making, planning of public health activities and the implementation of the Health in All Policies approach. The platform has proven transferable, sustainable and scalable across policies, data and regions

Meaningful Big Data Integration For a Global COVID-19 Strategy

Abstract With the rapid spread of the COVID-19 pandemic, the novel Meaningful Integration of Data Analytics and Services (MIDAS) platform quickly demonstrates its value, relevance and transferability to this new global crisis. The MIDAS platform enables the connection of a large number of isolated heterogeneous data sources, and combines rich datasets including open and social data, ingesting and preparing these for the application of analytics, monitoring and research tools. These platforms will assist public health author ities in: (i) better understanding the disease and its impact; (ii) monitoring the different aspects of the evolution of the pandemic across a diverse range of groups; (iii) contributing to improved resilience against the impacts of this global crisis; and (iv) enhancing preparedness for future public health emergencies. The model of governance and ethical review, incorporated and defined within MIDAS, also addresses the complex privacy and ethical issues that the developing pandemic has highlighted, allowing oversight and scrutiny of more and richer data sources by users of the system

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review

Alzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role of caregivers. This debilitating disease reportedly consumes 8% of the total United States healthcare expenditure, with medical and nursing outlays accounting for an estimated \$290 billion. Cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists have historically been the most widely used pharmacologic therapies for patients with AD; however, these drugs are not curative. The present investigation describes the epidemiology, pathophysiology, risk factors, presentation, and current treatment of AD followed by the role of the novel monoclonal antibody, Adulhelm, in the treatment of AD. Currently, Adulhelm is the only Food and Drug Administration (FDA) approved drug that acts to slow the progression of this disease. Adulhelm is an anti-amyloid drug that functions by selectively binding amyloid aggregates in both the oligomeric and fibrillar states. Studies show Adulhelm may help to restore neurological function in patients with AD by reducing beta-amyloid plaques and reestablishing neuronal calcium permeability. At present, there is concern the magnitude of this drug's benefit may only be statistically significant, although not clinically significant. Despite skepticism, Adulhelm has proven to significantly decrease amyloid in all cortical brain regions examined. With such high stakes and potential, further research into Adulhelm's clinical efficacy is warranted in the treatment of AD

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts

The 42nd Symposium Chromatographic Methods of Investigating Organic Compounds : Book of abstracts. June 4-7, 2019, Szczyrk, Polan